Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) Short Interest Down 78.8% in April

Posted by George Bondi on May 14th, 2026

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) was the recipient of a significant decrease in short interest in April. As of April 30th, there was short interest totaling 56,618 shares, a decrease of 78.8% from the April 15th total of 267,352 shares. Currently, 2.0% of the shares of the stock are short sold. Based on an average trading volume of 158,455 shares, the days-to-cover ratio is presently 0.4 days.

Cyclerion Therapeutics Stock Performance

CYCN traded down $0.04 on Thursday, hitting $3.09. 112,707 shares of the company were exchanged, compared to its average volume of 4,123,423. Cyclerion Therapeutics has a fifty-two week low of $1.03 and a fifty-two week high of $8.48. The firm has a market capitalization of $13.38 million, a P/E ratio of -2.27 and a beta of 1.80. The business’s fifty day moving average is $2.63 and its 200 day moving average is $1.89.

Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($17.20) by $16.44. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 58.21%. Analysts forecast that Cyclerion Therapeutics will post -1.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 75.62% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Cyclerion Therapeutics presently has an average rating of “Sell”.

Get Our Latest Report on Cyclerion Therapeutics

About Cyclerion Therapeutics

(Get Free Report)

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.